Human placental tissue is a therapeutic option in wound care as it can be readily available
Placental tissue is routinely discarded after birth; however, it can be easily collected with permission from the mothers of healthy babies at registered sites.
It also has low immunogenicity
Compared with other transplanted tissues, human placental tissue has low immunogenicity and therefore has a low risk of immune reactions and rejection. Several clinical studies have shown that allogeneic transplantation of the amniotic membrane does not induce acute immune rejection in the absence of immunosuppressive treatments.
This feature is associated with the low or limited surface expression of HLA class II (HLA-DR) and costimulatory molecules responsible for T cell activation. Immune tolerance is also mediated by active immunosuppressive properties of the tissue from the secretion of molecules, such as HLA-G, B7-H3, PD-L1 and PD-L2.
- Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of human amniotic membrane experimental xenotransplantation. Invest Ophthalmol Vis Sci. 2001;42(7):1539–1546.
- Magatti M, Vertua E, Cargoni A, Silini A, Parolini O. The immunomodulatory properties of amniotic cells: The two sides of the coin. Cell Transplant. 2018;27(1):31–44.
- Nikjaed H, Habibollah P, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008;15:88–99.
- Silini AR, Cargnoni A, Magatti M, Pianta S, Parolini O. The long path of human placenta and its derivatives, in regeneration medicine. Front Bioeng Biotechnol. 2015;3:162.